Skip to main content
Erschienen in: Diabetology International 1/2020

06.07.2019 | Original Article

Factors involved in body weight loss and its maintenance in morbidly obese inpatients

verfasst von: Rie Tadokoro, Tatsuya Iida, Kentaro Mikura, Hideyuki Imai, Norimitsu Murai, Mariko Kaji, Mai Hashizume, Yasuyoshi Kigawa, Kei Endo, Toru Iizaka, Fumiko Otsuka, Yoshitaka Iso, Takeyuki Sanbe, Shoichiro Nagasaka

Erschienen in: Diabetology International | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Body weight loss in patients with obesity improves abnormal glucose tolerance, dyslipidemia and hypertension; however, it is difficult to maintain this loss of body weight. The objective of this study was to examine factors involved in body weight loss and its maintenance in morbidly obese inpatients.

Method

The subjects were 31 patients (11 males and 20 females) who were admitted to hospital for obesity management. Factors involved in body weight changes during hospitalization and after discharge were examined retrospectively. The mean age was 58.1 ± 13.6 years and body mass index (BMI) was 40.2 ± 10.2 kg/m2. Twenty-four patients were complicated with type 2 diabetes mellitus. Diet therapy was 23.8 ± 3.9 kcal/kg ideal body weight/day.

Results

Excess weight loss (EWL) during hospitalization varied from 4.2 to 61.7%. Since EWL was affected by duration of hospital stay, the subjects were divided by the median of EWL per day. The subjects with greater EWL per day had lower body weight, BMI and fat mass on admission in the entire (n = 31), diabetic (n = 24), and non-diabetic subjects (n = 7), respectively. EWL per day was not different between diabetic and non-diabetic subjects. Follow-up data revealed that BMI remained unchanged 3 months after discharge but modestly increased 1 year after discharge, irrespective of EWL per day during hospitalization. In diabetic subjects followed up 1 year after discharge (n = 15), the increase in body weight was smaller than that in non-diabetic subjects (n = 3).

Conclusion

These results suggest that EWL in morbidly obese inpatients is greater than those with lower baseline BMI and fat mass. The presence of diabetes had no effects on EWL during hospitalization. EWL during hospitalization was not correlated with its maintenance after discharge. Diabetic patients displayed lesser degree of body weight gain after discharge, possibly due to the effects of anti-diabetic medications.
Literatur
1.
Zurück zum Zitat Committee on Obesity Diagnostic Criteria of the Japan Society for the Study of Obesity. New diagnostic criteria for obesity. Obes Res. 2000;6:18–28. Committee on Obesity Diagnostic Criteria of the Japan Society for the Study of Obesity. New diagnostic criteria for obesity. Obes Res. 2000;6:18–28.
2.
Zurück zum Zitat Examination Committee of Criteria for ‘Obesity Disease’ in Japan; Japan Society for the Study of Obesity. New criteria for ‘obesity disease’ in Japan. Circ J. 2002;66:987–92.CrossRef Examination Committee of Criteria for ‘Obesity Disease’ in Japan; Japan Society for the Study of Obesity. New criteria for ‘obesity disease’ in Japan. Circ J. 2002;66:987–92.CrossRef
3.
Zurück zum Zitat Muramoto A, Matsushita M, Kato A, Yamamoto N, Koike G, Nakamura M, Numata T, Tamakoshi A, Tsushita K. Three percent weight reduction is the minimum requirement to improve health hazards in obese and overweight people in Japan. Obes Res Clin Pract. 2014;8:e466–75.CrossRef Muramoto A, Matsushita M, Kato A, Yamamoto N, Koike G, Nakamura M, Numata T, Tamakoshi A, Tsushita K. Three percent weight reduction is the minimum requirement to improve health hazards in obese and overweight people in Japan. Obes Res Clin Pract. 2014;8:e466–75.CrossRef
4.
Zurück zum Zitat Japan Society for the Study of Obesity. Guidelines for obesity treatment in 2016. 1st ed. Tokyo: Life Science Publishing; 2016. p. 48–57. Japan Society for the Study of Obesity. Guidelines for obesity treatment in 2016. 1st ed. Tokyo: Life Science Publishing; 2016. p. 48–57.
5.
Zurück zum Zitat Elmer PJ, Grimm R Jr, Laing B, Grandits G, Svendsen K, Van Heel N, Betz E, Raines J, Link M, Stamler J, Neaton J. Lifestyle intervention: results of the Treatment of Mild Hypertension Study (TOMHS). Prev Med. 1995;24:378–88.CrossRef Elmer PJ, Grimm R Jr, Laing B, Grandits G, Svendsen K, Van Heel N, Betz E, Raines J, Link M, Stamler J, Neaton J. Lifestyle intervention: results of the Treatment of Mild Hypertension Study (TOMHS). Prev Med. 1995;24:378–88.CrossRef
6.
Zurück zum Zitat Hill JO, Wyatt HR, Reed GW, Peters JC. Obesity and the environment: where do we go from here? Science. 2003;299:853–5.CrossRef Hill JO, Wyatt HR, Reed GW, Peters JC. Obesity and the environment: where do we go from here? Science. 2003;299:853–5.CrossRef
7.
Zurück zum Zitat Heianza Y, Ma W, Huang T, Wang T, Zheng Y, Smith SR, Bray GA, Sacks FM, Qi L. Macronutrient intake-associated FGF21 genotype modifies effects of weight-loss diets on 2-year changes of central adiposity and body composition: the POUNDS lost trial. Diabetes Care. 2016;39:1909–14.CrossRef Heianza Y, Ma W, Huang T, Wang T, Zheng Y, Smith SR, Bray GA, Sacks FM, Qi L. Macronutrient intake-associated FGF21 genotype modifies effects of weight-loss diets on 2-year changes of central adiposity and body composition: the POUNDS lost trial. Diabetes Care. 2016;39:1909–14.CrossRef
8.
Zurück zum Zitat Yoshida T, Sakane N, Umekawa T, Sakai M, Takahashi T, Kondo M. Mutation of beta 3-adrenergic-receptor gene and response to treatment of obesity. Lancet. 1995;346:1433–4.CrossRef Yoshida T, Sakane N, Umekawa T, Sakai M, Takahashi T, Kondo M. Mutation of beta 3-adrenergic-receptor gene and response to treatment of obesity. Lancet. 1995;346:1433–4.CrossRef
9.
Zurück zum Zitat Campos GM, Rabl C, Mulligan K, Posselt A, Rogers SJ, Westphalen AC, Lin F, Vittinghoff E. Factors associated with weight loss after gastric bypass. Arch Surg. 2008;143:877–84.CrossRef Campos GM, Rabl C, Mulligan K, Posselt A, Rogers SJ, Westphalen AC, Lin F, Vittinghoff E. Factors associated with weight loss after gastric bypass. Arch Surg. 2008;143:877–84.CrossRef
11.
Zurück zum Zitat Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki N, Iwamoto Y, Kasuga M, Hanafusa T, Haneda M, Ueki K. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2010;1:212–28.CrossRef Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki N, Iwamoto Y, Kasuga M, Hanafusa T, Haneda M, Ueki K. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2010;1:212–28.CrossRef
12.
Zurück zum Zitat Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.CrossRef Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.CrossRef
13.
Zurück zum Zitat Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, Mohammed BS, Szapary PO, Rader DJ, Edman JS, Klein S. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med. 2003;348:2082–90.CrossRef Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, Mohammed BS, Szapary PO, Rader DJ, Edman JS, Klein S. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med. 2003;348:2082–90.CrossRef
14.
Zurück zum Zitat Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, McManus K, Champagne CM, Bishop LM, Laranjo N, Leboff MS, Rood JC, de Jonge L, Greenway FL, Loria CM, Obarzanek E, Williamson DA. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360:859–73.CrossRef Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, McManus K, Champagne CM, Bishop LM, Laranjo N, Leboff MS, Rood JC, de Jonge L, Greenway FL, Loria CM, Obarzanek E, Williamson DA. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360:859–73.CrossRef
15.
Zurück zum Zitat Harris J, Benedict F. A biometric study of human basal metabolism. Proc Natl Acad Sci USA. 1918;4:370–3.CrossRef Harris J, Benedict F. A biometric study of human basal metabolism. Proc Natl Acad Sci USA. 1918;4:370–3.CrossRef
16.
Zurück zum Zitat Liao HW, Saver JL, Wu YL, Chen TH, Lee M, Ovbiagele B. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open. 2017;7:e013927.CrossRef Liao HW, Saver JL, Wu YL, Chen TH, Lee M, Ovbiagele B. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open. 2017;7:e013927.CrossRef
17.
Zurück zum Zitat Balkau B, Home PD, Vincent M, Marre M, Freemantle N. Factors associated with weight gain in people with type 2 diabetes starting on insulin. Diabetes Care. 2014;37:2108–13.CrossRef Balkau B, Home PD, Vincent M, Marre M, Freemantle N. Factors associated with weight gain in people with type 2 diabetes starting on insulin. Diabetes Care. 2014;37:2108–13.CrossRef
18.
Zurück zum Zitat Sharma M, Beckley N, Nazareth I, Petersen I. Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis. BMJ Open. 2017;7:e017260.CrossRef Sharma M, Beckley N, Nazareth I, Petersen I. Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis. BMJ Open. 2017;7:e017260.CrossRef
19.
Zurück zum Zitat Hamblin PS, Wong R, Ekinci EI, Fourlanos S, Shah S, Jones AR, Hare MJL, Calder GL, Epa DS, George EM, Giri R, Kotowicz MA, Kyi M, Lafontaine N, MacIsaac RJ, Nolan BJ, O’Neal DN, Renouf D, Varadarajan S, Wong J, Xu S, Bach LA. SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission. J Clin Endocrinol Metab. 2019. https://doi.org/10.1210/jc.2019-00139.CrossRefPubMed Hamblin PS, Wong R, Ekinci EI, Fourlanos S, Shah S, Jones AR, Hare MJL, Calder GL, Epa DS, George EM, Giri R, Kotowicz MA, Kyi M, Lafontaine N, MacIsaac RJ, Nolan BJ, O’Neal DN, Renouf D, Varadarajan S, Wong J, Xu S, Bach LA. SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission. J Clin Endocrinol Metab. 2019. https://​doi.​org/​10.​1210/​jc.​2019-00139.CrossRefPubMed
20.
Zurück zum Zitat Huang KC, Kormas N, Steinbeck K, Loughnan G, Caterson ID. Resting metabolic rate in severely obese diabetic and nondiabetic subjects. Obes Res. 2004;12:840–5.CrossRef Huang KC, Kormas N, Steinbeck K, Loughnan G, Caterson ID. Resting metabolic rate in severely obese diabetic and nondiabetic subjects. Obes Res. 2004;12:840–5.CrossRef
21.
Zurück zum Zitat Alawad AO, Merghani TH, Ballal MA. Resting metabolic rate in obese diabetic and obese non-diabetic subjects and its relation to glycemic control. BMC Res Notes. 2013;6:382.CrossRef Alawad AO, Merghani TH, Ballal MA. Resting metabolic rate in obese diabetic and obese non-diabetic subjects and its relation to glycemic control. BMC Res Notes. 2013;6:382.CrossRef
22.
23.
Zurück zum Zitat Perri MG, Nezu AM, Patti ET, McCann KL. Effect of length of treatment on weight loss. J Consult Clin Psychol. 1989;57:450–2.CrossRef Perri MG, Nezu AM, Patti ET, McCann KL. Effect of length of treatment on weight loss. J Consult Clin Psychol. 1989;57:450–2.CrossRef
24.
Zurück zum Zitat Apolzan JW, Venditti EM, Edelstein SL, Knowler WC, Dabelea D, Boyko EJ, Pi-Sunyer X, Kalyani RR, Franks PW, Srikanthan P, Gadde KM, Diabetes Prevention Program Research Group. Long-term weight loss with metformin or lifestyle intervention in the Diabetes Prevention Program Outcomes Study. Ann Intern Med. 2019;170:682–90.CrossRef Apolzan JW, Venditti EM, Edelstein SL, Knowler WC, Dabelea D, Boyko EJ, Pi-Sunyer X, Kalyani RR, Franks PW, Srikanthan P, Gadde KM, Diabetes Prevention Program Research Group. Long-term weight loss with metformin or lifestyle intervention in the Diabetes Prevention Program Outcomes Study. Ann Intern Med. 2019;170:682–90.CrossRef
25.
Zurück zum Zitat Tewari N, Awad S, Macdonald IA, Lobo DN. A comparison of three methods to assess body composition. Nutrition. 2018;47:1–5.CrossRef Tewari N, Awad S, Macdonald IA, Lobo DN. A comparison of three methods to assess body composition. Nutrition. 2018;47:1–5.CrossRef
Metadaten
Titel
Factors involved in body weight loss and its maintenance in morbidly obese inpatients
verfasst von
Rie Tadokoro
Tatsuya Iida
Kentaro Mikura
Hideyuki Imai
Norimitsu Murai
Mariko Kaji
Mai Hashizume
Yasuyoshi Kigawa
Kei Endo
Toru Iizaka
Fumiko Otsuka
Yoshitaka Iso
Takeyuki Sanbe
Shoichiro Nagasaka
Publikationsdatum
06.07.2019
Verlag
Springer Japan
Erschienen in
Diabetology International / Ausgabe 1/2020
Print ISSN: 2190-1678
Elektronische ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-019-00403-y

Weitere Artikel der Ausgabe 1/2020

Diabetology International 1/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.